- US-listed companies
- Revolution Medicines, Inc.
- Income statement
Revolution Medicines, Inc.RVMD
Market cap
$14.5B
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 43 | 29 | 35 | 12 | - |
| Revenue growth (%) | - | - | |||
| Research & development | 132 | 187 | 253 | 423 | 592 |
| Operating margin (%) | - | ||||
| Operating income | -111 | -188 | -258 | -487 | -690 |
| Operating expenses | 154 | 217 | 294 | 499 | 690 |
| Income before tax | -109 | -187 | -249 | -440 | -601 |
| Pretax margin (%) | -252.5 | -636.6 | -704.1 | -3,798.7 | - |
| Provision for income taxes | -0 | - | -0 | -3 | -1 |
| Effective tax rate (%) | - | ||||
| Net income | -108 | -187 | -249 | -436 | -600 |
| Net income margin (%) | - | ||||
| Earnings per share | - | - | -3.08 | -3.86 | -3.58 |
| Diluted EPS | - | - | -3.08 | -3.86 | -3.58 |
| EBITDA | - | - | |||
| EBITDA margin (%) | - | - |